Avp-923
Agitation
Avanir PharmaceuticalsunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Agitation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Benha University | Phase 4 | BBB |
Haloperidol Benha University | Phase 4 | BBB |
Risperdal Abarbanel Mental Health Center | Phase 4 | BB |
Asenapine Unity Health Toronto | Phase 4 | BB |
Nabilone Sunnybrook Health Sciences Centre | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Avp-923 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →